These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24421422)

  • 1. Y-site compatibility of vancomycin and piperacillin/tazobactam at commonly utilized pediatric concentrations.
    Nichols KR; Demarco MW; Vertin MD; Knoderer CA
    Hosp Pharm; 2013 Jan; 48(1):44-7. PubMed ID: 24421422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulated Y-Site Compatibility of Vancomycin and Piperacillin-Tazobactam.
    Wade J; Cooper M; Ragan R
    Hosp Pharm; 2015 May; 50(5):376-9. PubMed ID: 26405323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compatibility of Vancomycin and Oxacillin During Simulated Y-Site Delivery.
    Teibel HM; Knoderer CA; Nichols KR
    Hosp Pharm; 2015 Sep; 50(8):710-3. PubMed ID: 26823620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.
    Meyer K; Santarossa M; Danziger LH; Wenzler E
    Hosp Pharm; 2017 Mar; 52(3):221-228. PubMed ID: 28439137
    [No Abstract]   [Full Text] [Related]  

  • 5. Y-site Incompatibility Between Premix Concentrations of Vancomycin and Piperacillin-Tazobactam: Do Current Compatibility Testing Methodologies Tell the Whole Story?
    Kufel WD; Miller CD; Johnson PR; Reid K; Zahra JJ; Seabury RW
    Hosp Pharm; 2017 Feb; 52(2):132-137. PubMed ID: 28321140
    [No Abstract]   [Full Text] [Related]  

  • 6. Physical compatibility of vancomycin and piperacillin sodium-tazobactam at concentrations typically used during prolonged infusions.
    Leung E; Venkatesan N; Ly SC; Scheetz MH
    Am J Health Syst Pharm; 2013 Jul; 70(13):1163-6. PubMed ID: 23784164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Visual and absorbance analyses of admixtures containing vancomycin and piperacillin-tazobactam at commonly used concentrations.
    O'Donnell JN; Venkatesan N; Manek M; Rhodes NJ; Scheetz MH
    Am J Health Syst Pharm; 2016 Feb; 73(4):241-6. PubMed ID: 26843502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration.
    Katip W
    Am J Health Syst Pharm; 2017 Jul; 74(14):1099-1102. PubMed ID: 28687555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF
    Am J Hosp Pharm; 1994 Mar; 51(5):672-8. PubMed ID: 8203388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Acute Kidney Injury With Concomitant Vancomycin and Piperacillin/Tazobactam Treatment Among Hospitalized Children.
    Downes KJ; Cowden C; Laskin BL; Huang YS; Gong W; Bryan M; Fisher BT; Goldstein SL; Zaoutis TE
    JAMA Pediatr; 2017 Dec; 171(12):e173219. PubMed ID: 28973124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and Risk Factors of Acute Kidney Injury in Patients Receiving Concomitant Vancomycin and Continuous-Infusion Piperacillin/Tazobactam: A Retrospective Cohort Study.
    Blair K; Covington EW
    Ann Pharmacother; 2020 Nov; 54(11):1096-1101. PubMed ID: 32406243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physical compatibility of ceftolozane-tazobactam with selected i.v. drugs during simulated Y-site administration.
    Thabit AK; Hamada Y; Nicolau DP
    Am J Health Syst Pharm; 2017 Jan; 74(1):e47-e54. PubMed ID: 28007721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications.
    Lee TM; Villareal CL; Meyer LM
    Hosp Pharm; 2021 Aug; 56(4):282-286. PubMed ID: 34381262
    [No Abstract]   [Full Text] [Related]  

  • 14. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions.
    Wilder AG; Foushee JA; Fox LM; Navalle J; Wright AM; Greer MA
    Int J Pharm Compd; 2020; 24(3):238-241. PubMed ID: 32401743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin-tazobactam.
    Burgess LD; Drew RH
    Pharmacotherapy; 2014 Jul; 34(7):670-6. PubMed ID: 24855041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of concomitant vancomycin and piperacillin-tazobactam on frequency of acute kidney injury in pediatric patients.
    Buhlinger KM; Fuller KA; Faircloth CB; Wallace JR
    Am J Health Syst Pharm; 2019 Aug; 76(16):1204-1210. PubMed ID: 31369115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute Kidney Injury in Pediatric Patients Treated with Vancomycin and Piperacillin-Tazobactam Versus Vancomycin and Cefotaxime: A Single-center Study.
    Alqurashi R; Batwa M; Alghamdi B; Aljohani S; Zaher N; Alzahrani A; Aldigs E; Safdar O
    Cureus; 2020 Jan; 12(1):e6805. PubMed ID: 32140363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
    Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
    Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperacillin-tazobactam versus cefepime incidence of acute kidney injury in combination with vancomycin and tobramycin in pediatric cystic fibrosis patients.
    LeCleir LK; Pettit RS
    Pediatr Pulmonol; 2017 Aug; 52(8):1000-1005. PubMed ID: 28440913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.